EyeGate technology featured in a Journal of Cataract and Refractive Surgery article

Hyaluronic acid (HA) is a key molecule identified for its wound-healing capacity in dermal and ocular injuries, however it is quickly degraded and cleared by the body limiting its effectiveness as a therapeutic. In this first-in-human exploratory pilot study, researchers evaluated the ability of a new and proprietary crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) ocular bandage gel to accelerate the healing of injuries to the surface of the cornea, such as those created during photorefractive keratectomy (PRK), a form of laser eye surgery used for vision correction. It was shown that the CMHA-S ocular bandage gel effectively and safely provided a hydrating and lubricating protectant on the surface of the eye facilitating accelerated healing of the cornea.

EyeGate Pharmaceutical’s first product from the CMHA-S platform is its proprietary Ocular Bandage Gel, which is an eye drop formulation applied topically to provide a thin coating to the surface of the eye serving as a protectant to facilitate and accelerate corneal injury healing.

A link to the full article can be found here.